NASDAQ:THAR Tharimmune (THAR) Stock Price, News & Analysis → Perma Bull: This is what terrifies me about AI (From InvestorPlace) (Ad) Free THAR Stock Alerts $0.37 -0.01 (-2.54%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$0.36▼$0.3950-Day Range$0.36▼$0.4752-Week Range$0.34▼$12.48Volume210,850 shsAverage Volume452,999 shsMarket Capitalization$4.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Tharimmune alerts: Email Address Ad Stansberry ResearchAmerica has a new type of money—should you get it?Is America's New Money right for you? I can't say... but I do know it's 100% legal and available to everyone... although precious few know much about it.Everything you need to know is posted on our website here. About Tharimmune Stock (NASDAQ:THAR)Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Read More THAR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THAR Stock News HeadlinesMay 2, 2024 | finance.yahoo.comStonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus ManagementApril 29, 2024 | americanbankingnews.comShort Interest in Tharimmune, Inc. (NASDAQ:THAR) Expands By 37.3%May 6, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 24, 2024 | finance.yahoo.comTharimmune, Inc. (THAR)April 18, 2024 | morningstar.comTharimmune Inc THARApril 16, 2024 | investing.comTharimmune forms advisory board to guide drug developmentFebruary 21, 2024 | msn.comTharimmune’s buccal film liver drug demonstrates effectiveness in Phase I trialFebruary 20, 2024 | msn.comTharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver DiseaseMay 6, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 20, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 20, 2024 | finance.yahoo.comTharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 9, 2024 | msn.comTharimmune’s Active Common Stock Shares UpdateFebruary 5, 2024 | finance.yahoo.comTharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary CholangitisJanuary 29, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business UpdateDecember 11, 2023 | finance.yahoo.comTharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease PatientsNovember 30, 2023 | finance.yahoo.comTharimmune, Inc. Announces Closing of $11 Million Public OfferingNovember 30, 2023 | msn.comWhy Tharimmune Stock (THAR) Is Down 70% TodayNovember 29, 2023 | msn.comWhy Is Liver Disease Focused Tharimmune Stock Trading Higher Today?November 29, 2023 | marketwatch.comTharimmune Shares Hit 52-Week Low After Public Offering PricesNovember 29, 2023 | msn.comTharimmune announces pricing of $10 million public offeringNovember 29, 2023 | markets.businessinsider.comCrude Oil Surges 2%; Tharimmune Shares PlummetNovember 29, 2023 | finance.yahoo.comTharimmune, Inc. Announces Pricing of $10 Million Public OfferingNovember 28, 2023 | investorplace.comWhy Is Tharimmune (THAR) Stock Down 70% Today?November 7, 2023 | investorplace.comWhy Is Tharimmune (THAR) Stock Up 113% Today?See More Headlines Receive THAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/06/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:THAR Previous SymbolNASDAQ:THAR CUSIPN/A CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($16.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-217.25% Return on Assets-159.07% Debt Debt-to-Equity RatioN/A Current Ratio6.03 Quick Ratio6.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.03 per share Price / Book0.03Miscellaneous Outstanding Shares11,740,000Free Float11,462,000Market Cap$4.34 million OptionableNot Optionable Beta1.61 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Randy D. Milby MBA (Age 70)President, Chairman & CEO Comp: $593.75kMr. Sireesh Appajosyula Pharm.D. (Age 48)COO & Director Comp: $584.8kMr. Thomas P. Hess CPA (Age 60)MBA, Chief Financial Officer Key CompetitorsArtelo BiosciencesNASDAQ:ARTLNexImmuneNASDAQ:NEXIExicureNASDAQ:XCURPetros PharmaceuticalsNASDAQ:PTPILipella PharmaceuticalsNASDAQ:LIPOView All CompetitorsInsidersRandy MilbyBought 29,000 shares on 12/15/2023Total: $14,500.00 ($0.50/share)Randy MilbyBought 10,000 shares on 11/30/2023Total: $10,000.00 ($1.00/share)View All Insider Transactions THAR Stock Analysis - Frequently Asked Questions How have THAR shares performed in 2024? Tharimmune's stock was trading at $0.5090 on January 1st, 2024. Since then, THAR stock has decreased by 27.3% and is now trading at $0.37. View the best growth stocks for 2024 here. Are investors shorting Tharimmune? Tharimmune saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 103,400 shares, an increase of 37.3% from the March 31st total of 75,300 shares. Based on an average daily trading volume, of 488,400 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.9% of the company's stock are short sold. View Tharimmune's Short Interest. When is Tharimmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our THAR earnings forecast. When did Tharimmune's stock split? Tharimmune's stock reverse split on the morning of Tuesday, November 21st 2023. The 1-25 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Tharimmune? Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:THAR) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersAI “wealth window” is closing June 25thParadigm PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.